Published in Am J Obstet Gynecol on April 21, 2006
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis (2010) 2.02
Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol (2012) 1.94
A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol (2007) 1.93
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe (2011) 1.50
Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest (2011) 1.44
Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. Clin Infect Dis (2015) 1.44
Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health (2008) 1.28
The microbiota of the vagina and its influence on women's health and disease. Am J Med Sci (2012) 1.11
Prevalence and risks for bacterial vaginosis in women who have sex with women. Sex Transm Dis (2010) 1.09
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. Microbiome (2013) 1.04
Emerging Sexual Health Issues Among Women Who Have Sex with Women. Curr Infect Dis Rep (2012) 1.02
Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin Trials (2007) 1.01
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00
Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol (2015) 1.00
Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol (2009) 0.99
The microbiota of the human genitourinary tract: trying to see the forest through the trees. Trans Am Clin Climatol Assoc (2012) 0.98
Comparison of the Effects of Myrtus Communis L, Berberis Vulgaris and Metronidazole Vaginal Gel alone for the Treatment of Bacterial Vaginosis. J Clin Diagn Res (2016) 0.96
Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis (2011) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother (2011) 0.95
Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis (2009) 0.94
The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics. Microb Ecol (2012) 0.90
Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis (2014) 0.87
Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sex Transm Dis (2011) 0.86
Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis (2013) 0.86
Olive oil based novel thermo-reversible emulsion hydrogels for controlled delivery applications. J Mater Sci Mater Med (2013) 0.86
Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. J Infect Dis (2014) 0.85
Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis (2015) 0.84
The posttrial effect of oral periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization. Sex Transm Dis (2012) 0.83
Establishing and sustaining a healthy vaginal environment: analysis of data from a randomized trial of periodic presumptive treatment for vaginal infections. J Infect Dis (2011) 0.82
Biological control of vaginosis to improve reproductive health. Indian J Med Res (2014) 0.80
A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect (2011) 0.80
Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis (2016) 0.78
Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Mater Sci Eng C Mater Biol Appl (2016) 0.77
Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infect Dis (2015) 0.77
Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure. Eur J Clin Microbiol Infect Dis (2014) 0.76
Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses. J Infect Dis (2016) 0.76
Bacterial vaginosis: Etiology and modalities of treatment-A brief note. J Pharm Bioallied Sci (2011) 0.75
Metronidazole gel prevents recurrences of bacterial vaginosis. J Fam Pract (2006) 0.75
Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial. Sex Transm Dis (2014) 0.75
Comparison between the efficacy of metronidazole vaginal gel and Berberis vulgaris (Berberis vulgaris) combined with metronidazole gel alone in the treatment of bacterial vaginosis. Electron Physician (2016) 0.75
BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial. Trials (2015) 0.75
Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome. PLoS One (2016) 0.75
A comparison of the efficacy of metronidazole vaginal gel and Myrtus (Myrtus communis) extract combination and metronidazole vaginal gel alone in the treatment of recurrent bacterial vaginosis. Avicenna J Phytomed (2017) 0.75
Elusive aetiology of bacterial vaginosis. Do lesbians have a clue? Sex Transm Infect (2007) 0.75
A cross-sectional study on the relationship of age, gestational age and HIV infection to bacterial vaginosis and genital mycoplasma infection. BMJ Open (2015) 0.75
Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb Ecol Health Dis (2017) 0.75
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med (2004) 4.30
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med (2009) 3.49
Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis (2003) 3.24
Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis (2003) 3.20
Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol (2002) 3.03
Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis (2012) 2.91
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2003) 2.86
Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis (2004) 2.48
Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis (2004) 2.24
Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis (2011) 2.19
Maternal complications with vaginal birth after cesarean delivery: a multicenter study. Am J Obstet Gynecol (2005) 2.14
Absence of ageism in access to critical care: a cross-sectional study. Age Ageing (2003) 2.14
The use of blunt needles does not reduce glove perforations during obstetrical laceration repair. Am J Obstet Gynecol (2008) 2.11
A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2008) 2.09
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One (2011) 1.94
A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94
Antimicrobial prophylaxis for cesarean delivery before skin incision. Obstet Gynecol (2009) 1.87
Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol (2002) 1.85
Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted? Am J Obstet Gynecol (2006) 1.75
Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol (2002) 1.73
Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. J Infect Dis (2005) 1.72
Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.71
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect (2007) 1.70
The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med (2002) 1.70
Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis (2003) 1.70
Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension (2004) 1.67
Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol (2004) 1.65
Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis (2004) 1.65
Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol (2007) 1.63
Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis (2005) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Alcohol and drug use and related disorders: An underrecognized health issue among adolescents and young adults attending sexually transmitted disease clinics. Sex Transm Dis (2006) 1.57
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized, controlled trial. Am J Obstet Gynecol (2007) 1.55
Quality of life utilities for pelvic inflammatory disease health states. Sex Transm Dis (2008) 1.54
Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis (2002) 1.54
Spectroscopic imaging as a triage test for cervical disease: a prospective multicenter clinical trial. J Low Genit Tract Dis (2007) 1.52
Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception (2006) 1.52
Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis (2003) 1.44
Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep (2014) 1.44
Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol (2004) 1.44
Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients. Int J Gynecol Cancer (2014) 1.43
Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis (2003) 1.38
The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2006) 1.35
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis (2007) 1.28
Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimens. J Clin Microbiol (2003) 1.26
Why women douche and why they may or may not stop. Sex Transm Dis (2003) 1.26
Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control (2003) 1.26
Primary care physician attitudes regarding sexually transmitted diseases. Sex Transm Dis (2002) 1.25
Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol (2004) 1.24
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr (2006) 1.24
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis (2009) 1.24
Association of sexual activity with colonization and vaginal acquisition of group B Streptococcus in nonpregnant women. Am J Epidemiol (2002) 1.24
Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol (2004) 1.21
Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol (2004) 1.20
Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex Transm Dis (2005) 1.19
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int (2005) 1.18
Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis (2005) 1.16
Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars. J Bacteriol (2012) 1.13
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J Infect Dis (2007) 1.12
DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol (2003) 1.11
Symptomatic urinary tract infections after surgery for prolapse and/or incontinence. Int Urogynecol J (2010) 1.11
Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol (2003) 1.10
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol (2003) 1.09
Improved methods for typing nontypeable isolates of group B streptococci. Int J Med Microbiol (2002) 1.09
Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol (2005) 1.09
Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis (2009) 1.08
Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. Am J Obstet Gynecol (2003) 1.08
Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis (2006) 1.08
Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque. Sex Transm Dis (2006) 1.07
Influenza transmission in a cohort of households with children: 2010-2011. PLoS One (2013) 1.07
Comment on "Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition". J Low Genit Tract Dis (2015) 1.07
Quantitative survival of aerobic and anaerobic microorganisms in Port-A-Cul and Copan transport systems. J Clin Microbiol (2008) 1.07
Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol (2005) 1.06
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment. Addict Behav (2010) 1.05
Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol (2012) 1.03
Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis (2009) 1.03
DNA macrorestriction analysis of nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J Clin Microbiol (2005) 1.03
Comparison of API 50 CH strips to whole-chromosomal DNA probes for identification of Lactobacillus species. J Clin Microbiol (2005) 1.02
Racial disparity in risk of preterm birth associated with lower genital tract infection. Paediatr Perinat Epidemiol (2007) 1.01
Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol (2012) 1.01